Technology-Delivered Cognitive-Behavioral Interventions for Alcohol Use: A Meta-Analysis.

Alcohol Treatment Cognitive-Behavioral Computer-Based Treatment Meta-Analysis Technology-Based Treatment

Journal

Alcoholism, clinical and experimental research
ISSN: 1530-0277
Titre abrégé: Alcohol Clin Exp Res
Pays: England
ID NLM: 7707242

Informations de publication

Date de publication:
11 2019
Historique:
received: 10 06 2019
accepted: 28 08 2019
pubmed: 1 10 2019
medline: 29 9 2020
entrez: 1 10 2019
Statut: ppublish

Résumé

Cognitive-behavioral therapy (CBT) has long-standing evidence for efficacy in the treatment of alcohol use, yet implementation in clinical practice has been challenging. Delivery of CBT through technology-based platforms, such as web-based programs and mobile applications, has the potential to provide widespread access to this evidence-based intervention. While there have been reviews indicating the efficacy of technology-based delivery of CBT for various psychiatric conditions, none have focused on efficacy for alcohol use. The current meta-analysis was conducted to fill this research gap. Descriptive data were used to characterize the nature of the literature on technology-delivered, CBT-based interventions for alcohol use ("CBT Tech"). Inverse-variance-weighted effect sizes were calculated, and random effects, effect sizes were pooled in 4 subgroups. Fifteen published trials conducted primarily with at-risk or heavy drinkers were identified. Of these studies, 60% explicitly targeted alcohol use moderation. The content of CBT Tech programs varied, ranging from 4 to 62 sessions/exercises, with many programs combining elements of motivational interviewing (47%). With respect to efficacy, CBT Tech as a stand-alone treatment in contrast to a minimal treatment control showed a positive and statistically significant, albeit small effect (g = 0.20: 95% CI = 0.22, 0.38, k These results show a benefit for technology-delivered, CBT-based interventions as a stand-alone therapy for heavy drinking or as an addition to usual care in specialty substance use settings.

Sections du résumé

BACKGROUND
Cognitive-behavioral therapy (CBT) has long-standing evidence for efficacy in the treatment of alcohol use, yet implementation in clinical practice has been challenging. Delivery of CBT through technology-based platforms, such as web-based programs and mobile applications, has the potential to provide widespread access to this evidence-based intervention. While there have been reviews indicating the efficacy of technology-based delivery of CBT for various psychiatric conditions, none have focused on efficacy for alcohol use. The current meta-analysis was conducted to fill this research gap.
METHODS
Descriptive data were used to characterize the nature of the literature on technology-delivered, CBT-based interventions for alcohol use ("CBT Tech"). Inverse-variance-weighted effect sizes were calculated, and random effects, effect sizes were pooled in 4 subgroups.
RESULTS
Fifteen published trials conducted primarily with at-risk or heavy drinkers were identified. Of these studies, 60% explicitly targeted alcohol use moderation. The content of CBT Tech programs varied, ranging from 4 to 62 sessions/exercises, with many programs combining elements of motivational interviewing (47%). With respect to efficacy, CBT Tech as a stand-alone treatment in contrast to a minimal treatment control showed a positive and statistically significant, albeit small effect (g = 0.20: 95% CI = 0.22, 0.38, k
CONCLUSIONS
These results show a benefit for technology-delivered, CBT-based interventions as a stand-alone therapy for heavy drinking or as an addition to usual care in specialty substance use settings.

Identifiants

pubmed: 31566787
doi: 10.1111/acer.14189
pmc: PMC6824956
mid: NIHMS1049851
doi:

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2285-2295

Subventions

Organisme : NIAAA NIH HHS
ID : R01 AA024122
Pays : United States
Organisme : NIAAA NIH HHS
ID : R21 AA026006
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2019 by the Research Society on Alcoholism.

Références

J Stud Alcohol. 1997 Jan;58(1):7-29
pubmed: 8979210
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
J Stud Alcohol Drugs. 2009 Jul;70(4):516-27
pubmed: 19515291
World Psychiatry. 2014 Oct;13(3):288-95
pubmed: 25273302
Drug Alcohol Depend. 2009 Feb 1;100(1-2):178-81
pubmed: 19041197
Depress Anxiety. 2016 Sep;33(9):783-91
pubmed: 27322710
Addiction. 2010 Aug;105(8):1381-90
pubmed: 20528806
Int J Behav Med. 2017 Oct;24(5):778-788
pubmed: 28224445
J Subst Abuse Treat. 2003 Sep;25(2):117-21
pubmed: 14680015
J Consult Clin Psychol. 2011 Jun;79(3):330-41
pubmed: 21534652
Alcohol Clin Exp Res. 2003 Jul;27(7):1107-22
pubmed: 12878917
Clin Psychol Rev. 2010 Jul;30(5):496-516
pubmed: 20488599
Alcohol Res Health. 2011;33(4):320-6
pubmed: 23580017
J Subst Abuse Treat. 2014 Jan;46(1):1-4
pubmed: 24041749
J Med Internet Res. 2015 Apr 29;17(4):e105
pubmed: 25925801
Am J Psychiatry. 2018 Sep 1;175(9):853-863
pubmed: 29792052
Addiction. 2008 Feb;103(2):218-27
pubmed: 18199300
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
J Anxiety Disord. 2018 Apr;55:70-78
pubmed: 29422409
Alcohol Clin Exp Res. 2016 Sep;40(9):1991-2000
pubmed: 27488212
JAMA. 2006 May 3;295(17):2003-17
pubmed: 16670409
Prev Sci. 2018 Nov;19(8):1091-1101
pubmed: 30136245
Harv Rev Psychiatry. 2017 May/Jun;25(3):123-134
pubmed: 28475504
J Consult Clin Psychol. 1997 Aug;65(4):686-93
pubmed: 9256570
Addiction. 2014 Feb;109(2):218-26
pubmed: 24134709
Cogn Behav Ther. 2015;44(3):190-211
pubmed: 25705787
Ir J Psychol Med. 2015 Sep;32(3):237-246
pubmed: 30185263
PLoS One. 2014 Jun 17;9(6):e99912
pubmed: 24937483
Lancet Psychiatry. 2017 Oct;4(10):775-818
pubmed: 28946952
J Med Internet Res. 2012 Nov 28;14(6):e166
pubmed: 23192752
Am J Psychiatry. 2014 Jun;171(6):683-90
pubmed: 24700332
Am Psychol. 2017 Oct;72(7):689-695
pubmed: 29016172
Curr Psychiatry Rep. 2010 Dec;12(6):547-52
pubmed: 20872100
Psychol Addict Behav. 2017 Dec;31(8):847-861
pubmed: 28857574
Addiction. 2019 Jan;114(1):9-15
pubmed: 29900624
Behav Ther. 2017 Mar;48(2):262-276
pubmed: 28270335
Alcohol Clin Exp Res. 2018 Dec;42(12):2453-2465
pubmed: 30395350
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
J Consult Clin Psychol. 2005 Feb;73(1):106-15
pubmed: 15709837
Addiction. 2009 Mar;104(3):378-88
pubmed: 19207345
Addict Behav. 2002 Nov-Dec;27(6):867-86
pubmed: 12369473
Adm Policy Ment Health. 2016 Jan;43(1):36-43
pubmed: 25491201
J Subst Abuse Treat. 2014 Jan;46(1):43-51
pubmed: 24060350
Addict Behav. 2000 Sep-Oct;25(5):769-74
pubmed: 11023017
J Clin Epidemiol. 2002 Jan;55(1):86-94
pubmed: 11781126
Drug Alcohol Depend. 2013 Dec 1;133(2):295-304
pubmed: 23747236
J Consult Clin Psychol. 2011 Apr;79(2):215-24
pubmed: 21319896
J Med Internet Res. 2013 Jul 11;15(7):e134
pubmed: 23846588
Addiction. 2014 Mar;109(3):394-406
pubmed: 24304463
Internet Interv. 2019 May 22;17:100251
pubmed: 31193584
Clin Psychol Rev. 2010 Jun;30(4):448-66
pubmed: 20304542
Subst Use Misuse. 2011;46(1):4-9
pubmed: 21190401
Drug Alcohol Depend. 2012 Jan 1;120(1-3):149-54
pubmed: 21831536
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Med J Aust. 2011 Aug 1;195(3):S44-50
pubmed: 21806518
Cogn Behav Ther. 2018 Jan;47(1):1-18
pubmed: 29215315
Am J Addict. 2001;10(s1):s51-s59
pubmed: 11268821
J Subst Abuse Treat. 2011 Apr;40(3):215-23
pubmed: 21185683
Am J Psychiatry. 2018 Jan 1;175(1):86-90
pubmed: 29301420
Am J Psychiatry. 2014 Apr;171(4):436-44
pubmed: 24577287
J Consult Clin Psychol. 2016 Nov;84(11):1008-1015
pubmed: 27599223
PLoS One. 2011 Mar 09;6(3):e14740
pubmed: 21408060
J Med Internet Res. 2012 Aug 01;14(4):e107
pubmed: 22954459
Am J Psychiatry. 2011 Aug;168(8):790-9
pubmed: 21536689
Am J Drug Alcohol Abuse. 2019;45(2):124-140
pubmed: 30373394
Alcohol Res Health. 1999;23(2):107-15
pubmed: 10890804
Am Psychol. 2010 Feb-Mar;65(2):73-84
pubmed: 20141263
Behav Res Ther. 2011 Jun;49(6-7):373-8
pubmed: 21492829
Clin Psychol Rev. 2018 Jul;63:80-92
pubmed: 29940401

Auteurs

Brian D Kiluk (BD)

From the, Yale University School of Medicine, (BDK), New Haven, Connecticut.

Lara A Ray (LA)

University of California at Los Angeles, (LAR), Los Angeles, California.

Justin Walthers (J)

Center for Alcohol and Addiction Studies, (JW, MB, MM), Brown University, Providence, Rhode Island.

Michael Bernstein (M)

Center for Alcohol and Addiction Studies, (JW, MB, MM), Brown University, Providence, Rhode Island.

Jeffery S Tonigan (JS)

University of New Mexico, (JST), Albuquerque, New Mexico.

Molly Magill (M)

Center for Alcohol and Addiction Studies, (JW, MB, MM), Brown University, Providence, Rhode Island.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH